The activity of erlotinib after gefitinib failure in non-small cell lung cancer patients with all
four favorable clinical factors including female, never smoker, Asian, and adenocarcinoma …

8023 Background: The purpose of the study was to evaluate the efficacy of erlotinib and the
feasibility of screening for EGFR mutations in advanced NSCLC p (chemonaive or relapsed …

8017 Background: Pts with EGFR-mutant lung cancers treated with EGFR tyrosine kinase
inhibitors (TKI) develop clinical resistance, most frequently due to acquisition of EGFR …

Purpose This is a phase II, multicenter, open-label study of chemotherapy-naïve patients
with non–small-cell lung cancer (NSCLC) and age≥ 70 years who were treated with …

Objectives Sequential combination of epidermal growth factor receptor (EGFR)-tyrosine
kinase inhibitors (TKIs) and chemotherapy has shown greater benefits than either treatment …

LBA7502 Background: Orally administered ARQ197 is a selective, non-ATP competitive
inhibitor of c-MET (MET), a receptor TK implicated in cancer cell migration, invasion, and …

Erlotinib is a relatively well-tolerated treatment option for patients with advanced non-small-
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …

Background: Erlotinib is a standard of treatment for metastatic non-small-cell lung cancer
after failure of initial therapy. Patient selection based on clinical factors is under discussion …

Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …

Objective There are few standard therapeutic options beyond second-line treatment. We
aimed to evaluate the efficacy and safety of erlotinib monotherapy as third-line …